Healthcare & Life Sciences · Flagship
The healthcare problems that cannot be run twice.
We advise hospitals, clinics, and diagnostic networks in the UAE and GCC on the decisions that carry real consequence. Healthcare strategy, operations, and market access are the core of the work. M&A runs where the portfolio has to move.
Where we are brought in
We are brought in when a healthcare problem reaches the level where the wrong call costs a year or the business itself.
- 01
Margin failure
A group is losing margin it cannot locate. The revenue is billed and the beds are full, but the cash does not arrive. We find where it leaks (coding, denials, collection, staffing ratios, capacity yield) and close the gap. We have taken a multi-specialty group from 4% EBITDA to double digits inside a year.
- 02
Entry at scale
An entry that has to work the first time, at size, against a competitive field and a payer system built differently in each emirate. We build the case on UAE unit economics, not the numbers that worked at home.
- 03
Turnaround and transformation
An operation running below benchmark, or a business that has outgrown the way it was built. We work the operational levers directly, not from the side of the table.
- 04
Capacity
Theatre utilisation, diagnostic yield, patient flow, staffing model: the difference between a facility that returns its capital and one that does not.
- 05
Consequence-level M&A
A buy-side deal for a fund, a sale that cannot be re-run, a merger where the licence, payer mix, and physician contracts hide liabilities the accounts do not show. We run diligence that reads the regulatory ground and valuation that reflects it.
How the practice converges
Five pillars converge on this sector. Strategy sets the entry and positioning. Transactions and capital run the deal and the raise. Market access opens the door. Operations recover the margin. Geopolitical advisory protects the continuity a hospital cannot suspend. The regulatory ground contact (DHA, DoH, MOHAP) was earned on live mandates, not read from guidelines.
On a mandate
A private equity fund asked us to run buy-side diligence on a UAE clinic group. The financials looked clean. The regulatory read did not: licensing gaps and physician contract weaknesses that supported a lower price and shaped the integration plan. The fund bought better, and we ran the re-licensing after close.
Questions
What clients ask first.
Where does margin actually leak in a UAE healthcare business?
Most often in the revenue cycle (coding accuracy, claims quality, denial management, and collection velocity) before staffing and procurement. It is the fastest EBITDA improvement available and the one operators consistently underestimate.
Do you advise on both Dubai and Abu Dhabi?
Yes, and the distinction matters. The payer frameworks, coding systems, and facility standards differ between DHA and DoH. Capability built for one is not capability for the other. We work both.
Can you run the M&A and the operations, or only one?
Both, and they are stronger together. The value in a healthcare deal often sits in the operational upside after close. We diligence it, then deliver it. That is rare in one advisor.
If you are working a healthcare decision that cannot be run twice, start with a conversation.